See the exciting findings from a study utilizing the NULISA Inflammation Panel 250 alongside Sapient’s mass spectrometry-based discovery proteomics and metabolomics to characterize changes in inflammatory markers observed following GLP-1 therapy.
Connect with our scientists to discuss your project or the biological questions you want to answer. We’re here to help you design and execute a high-impact study.
"*" indicates required fields
